Approach to oligometastatic disease in head and neck cancer, on behalf of the GORTEC.
Future Oncol
; 14(9): 877-889, 2018 Apr.
Article
em En
| MEDLINE
| ID: mdl-29578359
ABSTRACT
Median survival for recurrent/metastatic head and neck squamous cell cancer (HNSCC) patients is about 10 months after first-line best systemic treatment. We aimed to assess current approaches of oligometastatic HNSCC patients by the analysis of current concept and published data (1995-2017) in this population. Five-year survival rates are over 20% in selected patients who undergo metastasis-directed therapy by either surgery or stereotactic irradiation. Human papillomavirus(+) HNSCC patients have more disseminated metastases but respond more favorably and also benefit from ablative treatments. Treatments of oligometastases are expanding rapidly. Unmet needs include revised imaging follow-up strategies to detect metastases earlier, identification of predictive noninvasive biomarkers for treatment guidance, assessment and corrections of biases in current studies and randomized clinical trials.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Escamosas
/
Biomarcadores Tumorais
/
Neoplasias de Cabeça e Pescoço
/
Recidiva Local de Neoplasia
Tipo de estudo:
Clinical_trials
/
Guideline
Limite:
Humans
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
França